欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Angiogenesis > SU14813

浏览历史

S86019

SU14813

源叶(MedMol) 98%
  • 英文名:
  • SU14813
  • 别名:
  • SU14813; SU 14813; SU-14813; SU014813; SU-014813; SU 014813
  • CAS号:
  • 627908-92-3
  • 分子式:
  • C23H27FN4O4
  • 分子量:
  • 442.49
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S86019-5mg 98% ¥660.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S86019-10mg 98% ¥1180.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S86019-25mg 98% ¥2150.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S86019-100mg 98% ¥4900.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
  • 靶点: VEGFR1:2 nM (IC50);VEGFR2:50 nM (IC50);PDGFRβ:4 nM (IC50);KIT:15 nM (IC50);VEGFR;PDGFR;c-Kit
  • 体外研究:
    SU14813 inhibits ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets. SU14813 inhibits cellular ligand-dependent phosphorylation of VEGFR-2 (transfected NIH 3T3 cells), PDGFR-β (transfected NIH 3T3 cells), KIT (Mo7e cells), and FLT3-internal tandem duplication (FLT3-ITD; MV4;11 cells) as well as FMS/CSF1R (transfected NIH 3T3 cells). SU14813 inhibits VEGFR-2, PDGFR-β, and KIT phosphorylation in porcine aorta endothelial cells overexpressing these targets, with cellular IC50 values of 5.2, 9.9, and 11.2 nM, respectively. SU14813 inhibits the growth of U-118MG with an IC50 of 50 to 100 nM
  • 体内研究:
    SU14813 inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion. The plasma concentration required for in vivo target inhibition is estimated to be 100 to 200 ng/mL. Used as monotherapy, SU14813 exhibits broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduces growth of various established xenografts derived from human or rat tumor cell lines. Treatment in combination with docetaxel significantly enhances both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone
  • 参考文献:
    1. Patyna S, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.26 ml 11.3 ml 22.599 ml
    5 mM 0.452 ml 2.26 ml 4.52 ml
    10 mM 0.226 ml 1.13 ml 2.26 ml
    50 mM 0.045 ml 0.226 ml 0.452 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。